Abstract
Rationale: Short bowel syndrome with intestinal failure (SBS-IF) requires use of parenteral support (PS) and highly impacts patients (pts) quality of life (QoL). Teduglutide (TED), a GLP-2-analog, has proven efficacy reducing the need for PS. The study aimed to compare QoL in French TED vs non-TED pts.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have